Waters' Q1 Revenue Rises 10 Percent on Strength of Synapt G2, Acquity H-Class Uptake

Demand for the firm's newest instruments helped offset immaterial NIH stimulus spending and weaker-than-expected pharma sales.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.